Offerings // Allogene Therapeutics, Inc.

ALLO offering history

Every offering-related filing in Allogene Therapeutics, Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 572 filings back to Apr 19, 2018.

Last executed offering

Jun 22, 2026

424B5 — priced deal (shares or notes)

Last registration (announced)

Mar 14, 2024

S-3 — capacity, not a sale

Executed, last 12 months

424B pricings + 8-K 3.02 sales

Registered, last 12 months

S-1/S-3/F-series registrations

Date	Filing		What it means
Jun 22, 2026	424B5 →	EXECUTED	Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)
Apr 15, 2026	424B5 →	EXECUTED	Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)
Apr 13, 2026	424B5 →	EXECUTED	Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)
May 14, 2024	424B5 →	EXECUTED	Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)
Apr 25, 2024	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Mar 14, 2024	S-3 →	REGISTERED	S-3 registration — capacity to sell shares, not a sale yet
Nov 2, 2023	424B5 →	EXECUTED	Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)
Nov 2, 2022	S-3ASR →	REGISTERED	Automatic shelf registration — effective immediately (large filers)
Jun 3, 2020	424B5 →	EXECUTED	Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)
Jun 1, 2020	424B5 →	EXECUTED	Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)
Nov 5, 2019	S-3ASR →	REGISTERED	Automatic shelf registration — effective immediately (large filers)
Oct 11, 2018	424B4 →	EXECUTED	Final prospectus — offering priced (typical for IPOs and marketed share deals)
Oct 10, 2018	S-1MEF →	REGISTERED	S-1MEF registration — capacity to sell shares, not a sale yet
Oct 10, 2018	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Oct 5, 2018	S-1/A →	REGISTERED	S-1/A registration — capacity to sell shares, not a sale yet
Oct 2, 2018	S-1/A →	REGISTERED	S-1/A registration — capacity to sell shares, not a sale yet
Sep 17, 2018	S-1/A →	REGISTERED	S-1/A registration — capacity to sell shares, not a sale yet
Sep 14, 2018	S-1 →	REGISTERED	S-1 registration — capacity to sell shares, not a sale yet

ALLO offering-related filings from SEC EDGAR, newest first (capped at 40). Each links to the original document.

Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.

Is a shelf active now? →Do they need money? →Red flags →Full ALLO workspace →

ALLO offering FAQ

When did ALLO last execute an offering?

Per SEC filings, Allogene Therapeutics, Inc.'s most recent priced offering document is a 424B5 filed 2026-06-22. Note a 424B takedown can price shares or notes (debt) — the linked document says which.

When did ALLO last announce or register an offering?

The most recent registration is a S-3 filed 2024-03-14. A registration is capacity to sell shares — not a sale.

Does an offering always mean dilution?

Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.